4) was the negative control. Figure 1 Axitinib side effects HMGA2-positive expression in the moderately differentiated adenocarcinoma of gallbladder by means of EnVision immunohistochemistry. Figure 2 CD9-positive expression in the well-differentiated adenocarcinoma of gallbladder by means of EnVision immunohistochemistry. Figure 3 The survival curve of patients with HMGA2-positive or negative expression. Figure 4 The survival curve of patients with CD9-positive or negative expression. Statistical analysis All the experimental data were input using the SPPSS13.0 statistical package from SPSS Inc (Chicago,USA). The relationship between HMGA2 or CD9 expression and histological or clinical factors was analyzed by means of the ��2 test or Fisher’s exact test, and a P-value <0.05 was statistically significant.
The Kaplan-Meier method was used for univariate survival analysis (log-rank test), the Cox proportional hazards model was used for multivariate analysis, and Wald��s test was used to determine the 95% confidence interval. Results HMGA2 and CD9 expression in the gallbladder of benign and malignant lesions HMGA2 immunohistochemical positive reaction product was mainly localized in the nucleus (Figure (Figure1).1). CD9 immunohistochemical positive reaction product was localized in the cytoplasm and/or cell membrane (Figure (Figure2).2). As shown in Table Table1,1, HMGA2 expression of gallbladder adenocarcinoma was significantly higher than that of adjacent tissue, polyps and chronic cholecystitis gallbladder epithelium (P <0.01), but CD9 expression was the opposite (P <0.05 or P <0.01).
The gallbladder epithelium of benign gallbladder diseases with HMGA2-positive and CD9-negative expression appeared to be from moderate to severe dysplasia. Table 1 HMGA2 and CD9 expression in the gallbladder expression of benign and malignant lesions The relationship between HMGA2 and CD9 expression and clinicopathological features of gallbladder cancer The positive rates of HMGA2 were significantly lower in the cases of well-differentiated adenocarcinoma with a maximal diameter of mass <2 cm, no-metastasis of lymph node, and no-invasiveness of regional tissues than those of poorly-differentiated adenocarcinoma, maximal diameter of mass >2 cm, metastasis of lymph nodes, and invasiveness of regional tissues in gallbladder adenocarcinoma (P <0.05 or P <0.01), but the CD9 expression was the opposite (P <0.
05 or P <0.01). There was no significant relationship between HMGA2 and CD9 expression and other clinical and pathological features of gallbladder cancer (P >0.05, Table Table22). Table 2 The relationship between HMGA2 and CD9 expression and clinicopathological features of gallbladder cancer The relationship between HMGA2 and/or CD9 expression and survival Cilengitide time of patients with gallbladder cancer The data from 67 cases of 108 cases of gallbladder adenocarcinoma were obtained by letter or telephone interviews.